Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up

Clin Infect Dis. 2015 Aug 1;61(3):476-9. doi: 10.1093/cid/civ340. Epub 2015 Apr 26.

Abstract

In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen.

Keywords: HIV-1; extended-release formulation; long-term follow-up; nevirapine; pediatric patients.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Delayed-Action Preparations
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • Humans
  • Medication Adherence / statistics & numerical data
  • Nevirapine / administration & dosage
  • Nevirapine / adverse effects
  • Nevirapine / therapeutic use*

Substances

  • Anti-HIV Agents
  • Delayed-Action Preparations
  • Nevirapine